On September 29, 2020, the Friends of Cancer Research (Friends) 24th Annual Cancer Leadership Reception brought supporters together for a special town hall with the Nation’s top scientific leaders in the fight to treat and cure COVID-19 and cancer. Those exciting remarks and panels from experts in cancer and drug development are included below.
Dr. Francis Collins and Dr. Anthony Fauci Keynote Conversation
Dr. Francis Collins, Director of the National Institutes of Health (NIH), and Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), NIH,gave a thought provoking keynote conversation discussing the impact of the pandemic on research, how their work is evolving in 2020, and how they see the future of cancer research and drug development in the years to come.
Dr. Anthony Fauci Q&A
Dr. Anthony Fauci then addressed questions from the audience, discussing the importance of the Drug and Safety Monitoring Board (DSMB), and detailing the process for vaccine approval, touting the importance of the data monitoring system and experts involved.
Dr. Janet Woodcock, Dr. Peter Marks, and Dr. Mark McClellan
Following this discussion, Dr. Janet Woodcock, Therapeutic Lead of Operation Warp Speed at the U.S. Department of Health and Human Services, Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), FDA, and Dr. Mark McClellan, Director of the Duke-Margolis Center for Health Policy at Duke University and Former FDA Commissioner, conducted a conversation on COVID-19 and cancer. Dr. Woodcock focused her comments on Operation Warp Speed and the importance of the clinical trial process while Dr. Marks assured attendees that any Emergency Use Authorization (EUA) granted for a vaccine would require the same level of evidence as a full approval.
FDA Commissioner Stephen Hahn Opening Remarks
FDA Commissioner Stephen Hahn opened the event with opening remarks on the future of the agency in the world of cancer and it’s response to the pandemic.
24th Cancer Leadership Reception Sponsors
Pennie & Gary Abramson
The Rona and Jeffrey Abramson Foundation
Galena Yorktown Foundation
Ellen and Gerry Sigal
ACT for NIH
Maddy and Jim Berlin
Judy and Peter Blum Kovler Foundation
Merck & Co.
American Association for Cancer Research (AACR)
American Clinical Laboratory Association
Biotechnology Innovation Organization
Eli Lilly and Company
Greenleaf Health, Inc.
Richard and Rachel Klausner
David and Nicole Mitchell
Thrive Earlier Detection
Epstein Family Foundation
The Johns Hopkins University
Miriam and Sanford Ain
Dr. Jeffrey Akman and Mr. Steven Mazzola
Margaret Anderson and Jeffrey D’Eramo
Dr. Philip and Faith Bobrow
Catalyst Healthcare Consulting
Joel and Barbara Finkelstein
Lucy Fisher and Doug Wick
National Pharmaceutical Council
Palo Alto Investors
Steve Pomerantz and Karen Tandy
The Sherry Lansing Foundation
Robert C. Young, MD